Initial experience with a dual-balloon catheter for the management of postpartum hemorrhage - 25/01/14
and the
ebb Surveillance Study Team
Abstract |
Objective |
When uterotonics fail to cause sustained uterine contractions and satisfactory control of hemorrhage after delivery, tamponade of the uterus can be effective in decreasing hemorrhage secondary to uterine atony.
Study Design |
These data are from a postmarketing surveillance study of a novel dual-balloon catheter tamponade device, the Belfort-Dildy Obstetrical Tamponade System (ebb).
Results |
A total of 57 women were enrolled: 55 women had the diagnosis of postpartum hemorrhage, and 51 women had uterine balloon placement within the uterine cavity. This study reports the outcomes in the 51 women who had uterine balloon placement within the uterine cavity for treatment of postpartum hemorrhage, as defined by the “Instructions for Use.” We further assessed 4 subgroups: uterine atony only (n = 28 women), placentation abnormalities (n = 8 women), both uterine atony and placentation abnormalities (n = 9 women), and neither uterine atony nor placentation abnormalities (n = 6 women). The median (range) time interval between delivery and balloon placement was 2.2 hours (0.3–210 hours) for the entire cohort (n = 51 women) and 1.3 hours (0.5–7.0 hours) for the uterine atony only group (n = 28 women). Bleeding decreased in 22/51 of cases (43%), stopped in 28/51 of cases (55%), thus decreased or stopped in 50/51 of the cases (98%) after balloon placement. Nearly one-half (23/51) of all women required uterine balloon volumes of >500 mL to control bleeding.
Conclusion |
We conclude that uterine/vaginal balloon tamponade is very useful in the management of postpartum hemorrhage because of uterine atony and abnormal placentation.
Le texte complet de cet article est disponible en PDF.Key words : abnormal placentation, balloon tamponade, postpartum hemorrhage, uterine atony
Plan
| The remaining participants in the ebb Surveillance Study Team are listed in the Acknowledgments. |
|
| Supported by Glenveigh Medical. |
|
| G.A.D. and M.A.B. are the inventors and patent holders of the medical device described in this article. C.D.A. is Chairman and CSO of Glenveigh Medical, LLC, and its wholly owned subsidiary, Glenveigh Surgical, LLC (collectively, Glenveigh Medical), which is the manufacturer of the medical device described in this article. The remaining authors report no conflict of interest. |
|
| Reprints not available from the authors. |
|
| Cite this article as: Dildy GA, Belfort MA, Adair CD, et al. Initial experience with a dual-balloon catheter for the management of postpartum hemorrhage. Am J Obstet Gynecol 2014;210:136.e1-6. |
Vol 210 - N° 2
P. 136.e1-136.e6 - février 2014 Retour au numéro
Article précédent
- The Treatment of Obese Pregnant Women (TOP) study: a randomized controlled trial of the effect of physical activity intervention assessed by pedometer with or without dietary intervention in obese pregnant women
- Kristina M. Renault, Kirsten Nørgaard, Lisbeth Nilas, Emma M. Carlsen, Dina Cortes, Ole Pryds, Niels J. Secher
- High risk human papillomavirus at entry to prenatal care and risk of preeclampsia
- Mollie McDonnold, Holly Dunn, Ashley Hester, Luis D. Pacheco, Gary D.V. Hankins, George R. Saade, Maged M. Costantine
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?